<DOC>
	<DOCNO>NCT00673114</DOCNO>
	<brief_summary>Subjects diagnose hematological malignancy ( cancer blood ) , unlikely cured conventional non-transplant therapy . The best result bone marrow transplant obtain donor relative identical tissue type ( HLA-type ) . These subject donor available appropriately match unrelated umbilical cord blood unit ( UCB ) . However , cord blood unit contain high enough number cell may take long engraft ( grow ) . The purpose study determine whether addition stem cell family member supplement standard unrelated cord blood transplant safe increase success cord blood transplantation procedure . Subjects enrol study receive unrelated cord blood transplant plus haplo-identical ( half-matched ) , T-cell deplete stem transplant relate donor . The goal study determine whether addition relate stem cell accelerate bone marrow recovery improve long-term disease free survival .</brief_summary>
	<brief_title>Unrelated Cord Blood Transplant Plus Haplo-Identical ( Half-Matched ) , T-Cell Depleted Stem Transplant From Related Donor Subjects With High Risk Malignancies</brief_title>
	<detailed_description>Over past decade , umbilical cord blood transplantation show viable alternative donor stem cell source hematopoietic cell transplantation subject catastrophic disease treatable transplantation therapy . UCB cell cross partially mismatch HLA barrier without intolerable acute chronic Graft-versus-Host Disease ( GVHD ) . Thus , many subject lack sufficiently match , live relate unrelated bone marrow adult stem cell donor , use partially HLA-matched UCB cell stem cell rescue myeloablative irradiation and/or chemotherapy . UCB Cell dose , express per kilogram recipient body weight , best predictor outcomes UCB transplantation . Cell dose threshold strongly correlate outcome identify . In subject receive low cell dos , durable engraftment ultimately occur , significant delay myeloid platelet engraftment , best , result long hospitalization significant increase resource utilization bad case , result increase early death infection regimen-related toxicity . In infant child weigh &lt; 40kg , possible find sufficiently match UCB unit deliver dose cell critical successful engraftment ( defined 5 x 10^7 nucleated cells/kg ) within reasonable time frame &gt; 90 % subject . In teenager adult weigh &gt; 40kg , always possible . Because UCB unit contain relatively fix number total nucleated cell , unit deliver optimal cell dose subject weigh &gt; 70kg identify &lt; 10 % time . Attempts increase dose cell available UCBT include ex vivo expansion combine unit transplantation . While expansion UCB cell ex vivo possible , infusion expand cell result shorten engraftment time . Likewise , combination 5 UCB unit single myeloablative transplant shorten time neutrophil platelet engraftment . In study , take alternative approach facilitate early myeloid engraftment subject undergo UCB transplantation therapy . In subject identify donor delivering cell dose &gt; 2 x 10^7 nucleated cells/kg , augment UCBT low dose haplo-identical , T-cell deplete stem cell related adult donor facilitate early , short-term engraftment primary goal minimize early infection non-relapse mortality UCB cell engraft durable permanent graft . As immunocompetent UCB cell engraft , expect reject immunologically incompetent haplo-identical adult stem cell . Thus , approximately 100-180 day post transplant , subject convert 100 % donor chimerism UCB donor graft . In study , investigate use unrelated UCB obtain umbilical cord blood bank supplement related , haplo-identical , T-cell deplete stem cell subject high risk refractory malignancy , myelodysplasia severe aplastic anemia amenable stem cell transplantation therapy lack conventional related unrelated donor . OBJECTIVES : 1 . To determine safety co-transplantation unrelated umbilical cord blood supplement related , haplo-identical , T-cell deplete stem cell subject high risk malignancy . 2 . To describe rate neutrophil platelet engraftment immune reconstitution subject . 3 . To determine whether short long term lymphohematopoietic engraftment derive one donor source . The primary endpoint study number day ANC 500/uL The secondary endpoint study : 1 . 180 day survival 2 . Non-relapse mortality first 180 day post transplant 3 . Number day untransfused platelet count 50K/uL 4 . Incidence primary secondary graft failure 5 . Incidence severity acute chronic graft-versus-host disease ( GVHD ) 6 . Pace quality immune reconstitution 7 . Rates leukemic relapse 8 . Donor chimerism</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Patient Selection Criteria : Patients high risk refractory malignancy , myelodysplasia ( MDS ) severe aplastic anemia amenable stem cell transplantation therapy lack conventional related unrelated donor eligible trial . Have consent relate haploidentical ( 3/6 4/6 ) stem cell donor ; Have available 3 , 4 , 5 , 6/6 antigen matching unrelated UCB unit deliver cell dose 2.05.0 x 10e7cells/kg . Not consent 6/6 5/6 antigen match related bone marrow donor genetically match unrelated BM adult stem cell donor . Patients must &lt; 55 year age time study enrollment . Patients must histologically confirm diagnosis hematologic malignancy , MDS severe aplastic anemia . Eligible patient include follow : Patients high risk ALL first complete remission , high risk define presence hypodiploidy , ( 4 ; 11 ; MLL . 11q23 ) ( 9 ; 22 ) , patient present extreme hyperleukocytosis ( initial WBC &gt; 500,000/ml ) failure achieve complete remission standard induction therapy . All patient ALL ANLL second subsequent remission . Patients ALL ANLL relapse . Patients MDS . Patients CML chronic phase , accelerate phase blast crisis . Patients severe aplastic anemia refractory medical therapy . Patients must active CNS disease time study enrollment . Patients must good performance status ( Lansky 80100 % , Karnofsky 50100 % ) . Patients must adequate function organ system measure : Creatinine &lt; 2.0 mg/dl creatinine clearance &gt; 50 cc/min/m2 . Hepatic transaminase ( ALT/AST ) &lt; 4 x normal , bilirubin &lt; 2.0 mg/dl . Normal cardiac function echocardiogram radionuclide scan , ( ejection fraction shorten fraction &gt; 80 % normal value age ) . Pulmonary function test demonstrate FVC FEV1 &gt; 60 % predicted age . For adult patient DLCO &gt; 60 % predict . If patient perform PFTs , clearance pediatric adult pulmonologist require . Patients must uncontrolled infection time cytoreduction . Patient , parent , legal guardian must give write informed consent accord FDA guideline . Patients may pregnant lactate must current negative pregnancy test . Patients must minimum life expectancy least 3 month . Patients must available related haploidentical stem cell donor available unrelated cord blood donor deliver 2 x10e7 cells/kg 5 x 10e7 cells/kg match minimum 3/6 HLA locus . Patients must HIV negative . Patients must concurrently involve clinical trial affect engraftment immune reconstitution ( e.g . hematopoietic growth factor ) . Patients must comorbid condition , view Principal Investigators , render patient high risk treatment complication regimen related morbidity/mortality .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Haplo/cord</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>MDS</keyword>
	<keyword>Aplastic Anemia</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>CML</keyword>
</DOC>